Johanna Mercier

https://lnkd.in/gzpnNkCQ EXECUTIVE INTERVIEW - Lonza: Navigating Today’s Challenges in Drug Solubility & Bioavailability: Adi Kaushal, Director and Technology Head, Bioavailability Enhancement at Lonza, discusses solubility and bioavailability challenges and Lonza’s approach.

72

Omnichannel cannot function properly without clear, standardized data that is converted into insights and intelligence.

1

Having had the opportunity to support 4 of the 5 original BTK inhibitors that are FDA approved, it is exciting to see the evolving landscape, as highlighted in the recent article, reflect a significant shift in our approach to not just cancer but also autoimmune diseases. Sanofi’s rilzabrutinib shows considerable promise in treating conditions like immune thrombocytopenia and chronic spontaneous urticaria, underscoring the versatility of these therapies. It’s promising to see such innovations potentially expand to treat a range of autoimmune conditions. However, the discussion around the side effects and clinical holds serves as a critical reminder of the complexity of drug development. Ensuring patient safety must remain a top priority as we pursue these advanced therapeutic options. This balance between innovation and safety is what will truly drive our industry forward, offering new hopes and solutions to those in need.

17

To discuss how to de-risk your viral vector prior to clinical trials, please reach out to our team at #ISCT2024 in Vancouver. Farzin Farzaneh, PhD Traci Kyes Makis Sigalas

23

If you are heading to #synbiobeta2024 let us know! We would love to discuss how we can help your organization transform the work you are doing to #disrupt the world ZAETHER Derrek Evans Carrie F. John Seffernick

3

Big strides in MASH treatment with Madrigal Pharmaceuticals' Rezdiffra! But… is this the best there is? The recently FDA-approved therapy sets high expectations: •🏆 First-ever approved treatment for NASH, with potential to address a significant unmet medical need •🌐 Large market potential, with over 315,000 patients in need of therapy in the US and opportunities for global expansion •💡 Simple treatment: Oral once-daily dosing with no liver biopsy requirement However, challenges remain ahead: •🛠️ First Commercial Product: Madrigal lacks prior commercialization experience •📈 Market Development: Significant efforts are needed to establish a MASH treatment paradigm and prep the market for Rezdiffra •⚔️ Intensifying Competition: crowded competitive landscape with potential multiple launches in the next five years from #NovoNordisk #Inventiva #Akero #89Bio #Pfizer #BoehringerIngelheim For full access to this analysis, comment below 👇 To dive deeper into the evolving landscape of MASH, email us at 📥 info@atacana.com #MASH #rezdiffra #madrigaltherapeutics #competitiveintelligence #pharma #pharmaceuticals #biotech 

69

4 Comments

I am excited to moderate the panel on this provocative topic "Is the Hype of AI Over for Drug Discovery?". I am grateful to the knowledgeable and passionate participants on the panel and look forward to an interesting discussion. #PDDPSUMMIT 

7

It’s time for pharma to rethink deployment models to meet evolving customer needs, as customer engagement preferences for both channel and frequency continue to change. My colleagues Scott Cohen and Megan Jackson take a closer look at declining access trends, address some of the top field deployment questions and offer tangible steps to evolve sales planning efforts. #oncology #pharma #futurecommercialmodel https://lnkd.in/eMEqApbn

12

Departing Words: Merck’s Ken Frazier Cautions Against Profit Maximization Pharma CEOs must balance optimizing access and profitability, former Merck CEO and soon-to-be ex executive chairman of the company said. Frazier says health care industry must come to table and admit the “system ain’t working,” talks about the need to protect democracy, in a sweeping interview at the STAT Summit. ....from the Citeline archives, via Sarah Karlin-Smith ********** In a court filing reported yesterday by Bloomberg Law reporter Celine Castronuovo, Amgen argues it will suffer “concrete harm” unless a federal judge quickly enjoins Colorado’s drug pricing board from moving forward with a payment cap for Enbrel. Like nearly all content in healthcare today, Amgen's storyline starts and sticks with the Standard Model, the cut-and-paste messaging that now sits at the extreme end of monotonous repetition. To wit: "Innovative medicines have enhanced and extended the lives of countless Coloradans. Recognizing the enormous investment of time and money needed to discover and develop these novel treatments, Congress rewarded those who bring new medicines to market with a period of patent exclusivity and pricing discretion. As numerous scholars have observed, the economic incentives provided by the federal patent system are crucial to Congress’s objective of promoting pharmaceutical research and development. One such medicine, Amgen’s pioneering drug ENBREL® provides life-changing relief to thousands of Coloradans who suffer from arthritis and other autoimmune diseases. Enbrel redefined the clinical course of moderate to severe rheumatoid arthritis...." etc., etc., etc., etc. All of which may be technically true, as "the scholars have observed", but if the objective for Amgen is an argument that persuades, the #StandardModel stopped working long ago. It also doesn't help when the 20 members of the Colorado drug pricing board and its advisory council come home from work and watch the local news, where the commercial breaks will be flooded with drug promotion, part of the media buy that comes from the industry spending $30 billion/year on DTC advertising. These things are connected. In a conversation with Bill Boulding, Dean of Duke University - The Fuqua School of Business around the same time as his interview with STAT, Frazier said one of the role's of business was in collaborating with government to reinvent the country. “The role of the private sector in the United States in helping to reinvent this country, over, and over, and over again, is important,” he said. “I think business has the talent, it has the resources, it has the capabilities of helping to change our country.” It's time to sweep the old concepts out of the saddle. The faster the drug market learns how to connect things differently, to 'see, say, sell and sustain' strategy at a system level, the faster it can start creating a different future for itself. #QuentinTarantino

10

1 Comment

A few months back I was driving home listening to a podcast and it resonated so strongly that I pulled over and called members of the Immunitas Therapeutics executive team to ask them to listen to it.  The podcast was a Slate Magazine #PoliticalGabfestReads episode in which John Dickerson interviewed Brad Stulberg about his new book #MasterofChange. Podcast link at bottom. Many of the personal themes of the book can also apply to companies and teams. Those early conversations from my car grew into a robust offsite discussion; our full exec team listened to the podcast and then talked through a discussion guide, attached here. #Change is constantly happening to and around us. Our team started to list how many “major life changes” the company has been through since we were founded in 2019, both positive and challenging. We easily jotted down 22+ (#startup 😁). On the positive side, we started dosing our novel therapy in cancer patients in the clinic, nominated new programs, raised venture funding, and hired key executives, among many others. The changes aren't stopping anytime soon. We are constantly growing the depth of our #science and the #expertise of our people, and the external world will continue to shift. The podcast and attached team discussion guide are applicable to a variety of industries, management levels, and companies. Please feel welcome to share and use. The podcast takes about 30min to listen to. One of the most fascinating aspects of the discussion was what we learned about each other's backgrounds, professional experience, and values, in addition to having a significant strategic discussion about thriving in an evolving world. Thanks to Char Gross and Lynette Herscha for editorial feedback and the Immunitas Therapeutics exec team for bringing their thoughtfulness, insights, and openness to the discussion. Ditto to John Dickerson #EmilyBazelon and David Plotz for a great podcast series. #thrive #evolve #teambuilding #strategy Podcast Link: https://lnkd.in/gdXfRmYB

38

5 Comments

We started out Q1 with cautious optimism and the numbers continue to show the confidence was warranted. Biopharma M&A activity more than doubled nationally during the year’s first three months, coinciding with a rebound in venture capital deals as well as a flurry of IPOs. These are all good signs that the drug development cycle is normalizing and should translate into additional funding being available at the seed and Series A stages. Certain to be on the minds of funders and startups attending #AlignSummit24 on Thursday! https://lnkd.in/erEiJm6S  

112

5 Comments

We are thrilled to announce that iRegene has received US FDA IND approval for NouvNeu001, our innovative therapy targeting Parkinson's disease. This is a significant milestone in our mission to develop groundbreaking treatments for neurodegenerative disorders. At iRegene, we are dedicated to advancing neurodegenerative disease research and are excited about the potential impact of NouvNeu001 on the lives of those affected by Parkinson's. This approval brings us one step closer to providing a novel therapeutic option for patients in need. We extend our heartfelt gratitude to our partners, researchers, and supporters who have contributed to this achievement. #iRegene #ParkinsonsDisease #NouvNeu001 #FDAApproval #ClinicalTrials #NeurodegenerativeResearch #InnovationInHealthcare #Biotechnology

81

6 Comments

As we move past the 4th of July holiday, it's crucial to pause for a mid-year review of trends shaping our biopharma industry: Growth of Advanced Modalities: Biopharma companies are heavily investing in cutting-edge treatments like gene therapies and RNA-based therapeutics, paving the way for addressing previously untreatable diseases. Global Pricing Pressure: Pricing negotiations remain complex as governments, payers, and patients demand transparency and affordability, challenging companies to balance innovation and access to life-saving therapies. Evolving Commercialization Models: The shift towards direct-to-consumer approaches, digital marketing, and patient-centric strategies is transforming traditional commercialization models, accelerated by telemedicine and virtual engagement trends from the recent pandemic. Focus on Patient Diagnosis and Biomarkers: Biomarker-driven endpoints in clinical trials are on the rise, optimizing patient outcomes through tailored treatments and minimizing adverse effects. Evolving Financing Landscape: Biopharma firms are diversifying financing sources through partnerships, licensing deals, and public offerings, with special purpose acquisition companies (SPACs) influencing funding strategies. The biopharma industry's dynamic nature requires adaptable partners. Discover how WEP Clinical can support your success amidst these industry shifts at wepclinical.com. Let's connect and discuss how we can excel together in these changing times.

11

How can life science organizations meet the needs of the evolving US healthcare landscape while maintaining patient centricity? This article outlines ways the Alnylam Strategic Account Management program is achieving this mission. https://lnkd.in/ghcxUPYb

53

7 Comments